Perioperative antibiotic prophylaxis in paediatric cardiac surgery

Cardiology in the Young

Volumn 17, Issue 1, 2007, Pages 12-25

  Alphonso, Nelson ^a   Anagnostopoulos, Petros V ^a   Scarpace, Sarah ^b   Weintrub, Peggy ^b   Azakie, Anthony ^a   Raff, Gary ^a   Karl, Tom R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Congenital cardiac malformations; Pharmacology; Therapeutics

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFALOTIN; CEFAMANDOLE; CEFAZEDONE; CEFAZOLIN; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; FLUCLOXACILLIN; FLUCONAZOLE; GENTAMICIN; KANAMYCIN; MEROPENEM; METICILLIN; NORADRENALIN; OXACILLIN; PENICILLIN G; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BRONCHOSPASM; CARDIOPULMONARY BYPASS; CATHETER INFECTION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEVICE REMOVAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FLUSHING; HEART ARREST; HEART SURGERY; HEART VALVE SURGERY; HUMAN; HYPOTENSION; INCIDENCE; INFECTION RISK; MEDIASTINITIS; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PEDIATRIC SURGERY; PERIOPERATIVE PERIOD; PREVALENCE; REVIEW; RISK REDUCTION; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SURGICAL INFECTION; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIBIOTIC PROPHYLAXIS; CARDIAC SURGICAL PROCEDURES; CHEST TUBES; DRUG RESISTANCE, MICROBIAL; HUMANS; PEDIATRICS; PERIOPERATIVE CARE;

EID: 33847299026     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951107000066     Document Type: Review

References (111)

1. Crabtree TD, Codd JE, Fraser VJ, Bailey MS, Olsen MA, Damiano Jr RJ, Multivariate analysis of risk factors for deep and superficial sternal infection after coronary artery bypass grafting at a tertiary care medical center. Semin Thorac Cardiovasc Surg 2004; 16: 53-61.
2. Olsen MA, Lock-Buckley P, Hopkins D, Polish LB, Sundt TM, Fraser VJ. The risk factors for deep and superficial chest surgical-site infections after coronary artery bypass graft surgery are different. J Thorac Cardiovasc Surg 2002; 124: 136-145.
3. Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: Incidence, risk factors and mortality. Eur J Cardiothorac Surg 2001; 20: 1168-1175.
4. Braxton JH, Martin CA, McGrath PD, et al. 10-year follow-up of patients with and without mediastinitis. Semin Thorac Cardiovasc Surg 2004; 16: 70-76.
5. Tang GH, Maganti M, Weisel RD, Borger MA. Prevention and management of deep sternal wound infection. Semin Thorac Cardiovasc Surg 2004; 16: 62-69.
6. Lu JC, Grayson AD, Jha P, Srinivasan AK, Fabri BM. Risk factors for sternal wound infection and mid-term survival following coronary artery bypass surgery. Eur J Cardiothorac Surg 2003; 23: 943-949.
7. Demmy TL, Park SB, Liebler GA, et al. Recent experience with major sternal wound complications. Ann Thorac Surg 1990; 49: 458-462.
8. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: A meta-analysis. Clin Infect Dis 2004; 38: 1357-1363.
9. Kriaras I, Michalopoulos A, Michalis A, et al. Antibiotic prophylaxis in cardiac surgery. J Cardiovasc Surg (Torino) 1997; 38: 605-610.
10. Curtis JJ, Boley TM, Walls JT, Hamory B, Schmaltz RA. Randomized, prospective comparison of first- and second-generation cephalosporins as infection prophylaxis for cardiac surgery. Am J Surg 1993; 166: 734-737.
11. Niederhauser U, Vogt M, Vogt P, Genoni M, Kunzli A, Turina MI. Cardiac surgery in a high-risk group of patients: Is prolonged postoperative antibiotic prophylaxis effective? J Thorac Cardiovasc Surg 1997; 114: 162-168.
12. Sandoe JA, Kumar B, Stoddart B, et al. Effect of extended peri-operative antibiotic prophylaxis on intravascular catheter colonization and infection in cardiothoracic surgery patients. J Antimicrob Chemother 2003; 52: 877-879.
13. Mossad SB, Serkey JM, Longworth DL, Cosgrove DM, III, Gordon SM. Coagulase-negative staphylococcal sternal wound infections after open heart operations. Ann Thorac Surg 1997; 63: 395-401.
14. Carrier M, Marchand R, Auger P, et al. Methicillin-resistant Staphylococcus aureus infection in a cardiac surgical unit. J Thorac Cardiovasc Surg 2002; 123: 40-44.
15. Kovacikova L, Kunovsky P, Skrak P, Hraska V, Kostalova L, Tomeckova E. Thyroid hormone metabolism in pediatric cardiac patients treated by continuous povidone-iodine irrigation for deep sternal wound infection. Eur J Cardiothorac Surg 2002; 21: 1037-1041.
16. Tortoriello TA, Friedman JD, McKenzie ED, et al. Mediastinitis after pediatric cardiac surgery: A 15-year experience at a single institution. Ann Thorac Surg 2003; 76: 1655-1660.
17. Ohye RG, Maniker RB, Graves HL, Devaney EJ, Bove EL. Primary closure for postoperative mediastinitis in children. J Thorac Cardiovasc Surg 2004; 128: 480-486.
18. Al Sehly AA, Robinson JL, Lee BE, et al. Pediatric poststernotomy mediastinitis. Ann Thorac Surg 2005; 80: 2314-2320.
19. Huddleston CB. Mediastinal wound infections following pediatric cardiac surgery. Semin Thorac Cardiovasc Surg 2004; 16: 108-112.
20. Kittle CF, Reed WA. Antibiotics and extracorporeal circulation. J Thorac Cardiovasc Surg 1961; 41: 34-48.
21. Goodman JS, Schaffner W, Collins HA, Battersby EJ, Koenig MG. Infection after cardiovascular surgery. Clinical study including examination of antimicrobial prophylaxis. N Engl J Med 1968; 278: 117-123.
22. Fekety Jr FR, Cluff LE, Sabiston DC, Jr., Seidl LG, Smith JW, Thoburn R. A study of antibiotic prophylaxis in cardiac surgery. J Thorac Cardiovasc Surg 1969; 57: 757-763.
23. Fong IW, Baker CB, McKee DC. The value of prophylactic antibiotics in aorat-coronary bypass operations: A double-blind randomized trial. J Thorac Cardiovasc Surg 1979; 78: 908-913.
24. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992; 104: 590-599.
25. Slama TG, Sklar SJ, Misinski J, Fess SW. Randomized comparison of cefamandole, cefazolin, and cefuroxime prophylaxis in open-heart surgery. Antimicrob Agents Chemother 1986; 29: 744-747.
26. Kaiser AB, Petracek MR, Lea JW, et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double-blind trial in 1030 patients. Ann Surg 1987; 206: 791-797.
27. Geroulanos S, Oxelbark S, Donfried B, Recker F, Turina M. Antimicrobial prophylaxis in cardiovascular surgery. Thorac Cardiovasc Surg 1987; 35: 199-205.
28. Conklin CM, Gray RJ, Neilson D, Wong P, Tomita DK, Matloff JM. Determinants of wound infection incidence after isolated coronary artery bypass surgery in patients randomized to receive prophylactic cefuroxime or cefazolin. Ann Thorac Surg 1988; 46: 172-177.
29. Doebbeling BN, Pfaller MA, Kuhns KR, Massanari RM, Behrendt DM, Wenzel RP. Cardiovascular surgery prophylaxis. A randomized, controlled comparison of cefazolin and cefuroxime. J Thorac Cardiovasc Surg 1990; 99: 981-989.
30. Townsend TR, Reitz BA, Bilker WB, Bartlett JG. Clinical trial of cefamandole, cefazolin, and cefuroxime for antibiotic prophylaxis in cardiac operations. J Thorac Cardiovasc Surg 1993; 106: 664-670.
31. Maki DG, Bohn MJ, Stolz SM, Kroncke GM, Acher CW, Myerowitz PD. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg 1992; 104: 1423-1434.
32. Salminen US, Viljanen TU, Valtonen VV, Ikonen TE, Sahlman AE, Harjula AL. Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. J Antimicrob Chemother 1999; 44: 287-290.
33. Spelman D, Harrington G, Russo P, Wesselingh S. Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol 2002; 23: 402-404.
34. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002; 123: 326-332.
35. Bertolissi M, Bassi F, Cecotti R, Capelli C, Giordano F. Pruritus: A useful sign for predicting the haemodynamic changes that occur following administration of vancomycin. Crit Care 2002; 6: 234-239.
36. Levy JH, Marty AT. Vancomycin and adverse drug reactions. Crit Care Med 1993; 21: 1107-1108.
37. Levy JH. Anaphylactic/anaphylactoid reactions during cardiac surgery. J Clin Anesth 1989; 1: 426-430.
38. Levy JH, Kettlekamp N, Goertz P, Hermens J, Hirshman CA. Histamine release by vancomycin: A mechanism for hypotension in man. Anesthesiology 1987; 67: 122-125.
39. Valero R, Gomar C, Fita G, et al. Adverse reactions to vancomycin prophylaxis in cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5: 574-576.
40. Polk RE. Anaphylactoid reactions to glycopeptide antibiotics. J Antimicrob Chemother 1991; 27 (Suppl B): 17-29.
41. Best CJ, Ewart M, Sumner E. Perioperative complications following the use of vancomycin in children: A report of two cases. Br J Anaesth 1989; 62: 576-577.
42. Southorn PA, Plevak DJ, Wright AJ, Wilson WR. Adverse effects of vancomycin administered in the perioperative period. Mayo Clin Proc 1986; 61: 721-724.
43. Wade TP, Mueller GL. Vancomycin and the "red-neck syndrome". Arch Surg 1986; 121: 859-860.
44. Holliman R. "Red man syndrome" associated with rapid vancomycin infusion. Lancet 1985; 1: 1399-1400.
45. Forestner JE, Wright JA. Vancomycin-induced hypotension in a child with congenital heart disease. Clin Pediatr (Phila) 1984; 23: 416.
46. Dajee H, Laks H, Miller J, Oren R. Profound hypotension from rapid vancomycin administration during cardiac operation. J Thorac Cardiovasc Surg 1984; 87: 145-146.
47. Newfield P, Roizen MF. Hazards of rapid administration of vancomycin. Ann Intern Med 1979; 91: 581.
48. Mercieri M, Mercieri A, Tritapepe L, et al. High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting. Br J Anaesth 1999; 82: 531-536.
49. Stier GR, McGory RW, Spotnitz WD, Schwenzer KJ. Hemodynamic effects of rapid vancomycin infusion in critically ill patients. Anesth Analg 1990; 71: 394-399.
50. Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Antihistamine prophylaxis permits rapid vancomycin infusion. Crit Care Med 1999; 27: 1732-1737.
51. Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Oral antihistamines reduce the side effects from rapid vancomycin infusion. Anesth Analg 1998; 87: 681-685.
52. Renz C, Lynch J, Thurn J, Moss J. Histamine release during rapid vancomycin administration. Inflamm Res 1998; 47 (Suppl 1): S69-S70.
53. Romanelli VA, Howie MB, Myerowitz PD, et al. Intraoperative and postoperative effects of vancomycin administration in cardiac surgery patients: A prospective, double-blind, randomized trial. Crit Care Med 1993; 21: 1124-1131.
54. Mascini EM, Bonten MJ. Vancomycin-resistant enterococci: Consequences for therapy and infection control. Clin Microbiol Infect 2005; 11 (Suppl 4): 43-56.
55. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: Epidemiology and control. Curr Opin Infect Dis 2005; 18: 300-305.
56. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493-501.
57. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-721.
58. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001; 41: 927-934.
59. O'Rullian JJ, Wise RK, McCoach RM, Kingsley CP, Williams DR. The effects of haemofiltration on cefazolin levels during cardiodiopulmonary bypass. Perfusion 1998; 13: 176-180.
60. Williams BS, Ransom JL, Gal P, Carlos RQ, Smith M, Schall SA. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Crit Care Med 1997; 25: 273-275.
61. Heylen RM, Wilson AP, Hichens M, et al. Antibiotic prophylaxis in cardiac surgery: Factors associated with potentially toxic serum concentrations of gentamicin. J Antimicrob Chemother 1995; 35: 657-667.
62. Heylen RM, Wilson AP, Hichens M, et al. Clearance of gentamicin during cardiac surgery. J Antimicrob Chemother 1995; 35: 649-655.
63. Mazzarella V, Galluci MT, Tozzo C, et al. Renal function in patients undergoing cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 1992; 104: 1625-1627.
64. Lehot JJ, Reverdy ME, Etienne J, et al. Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Anesth 1990; 4: 204-209.
65. Lehot JJ, Reverdy ME, Etienne J, et al. Oxacillin and tobramycin serum levels during cardiopulmonary bypass. J Cardiothorac Anesth 1989; 3: 163-167.
66. Haessler D, Reverdy ME, Neidecker J, Brule P, Ninet J, Lehot JJ. Antibiotic prophylaxis with cefazolin and gentamicin in cardiac surgery for children less than ten kilograms. J Cardiothorac Vasc Anesth 2003; 17: 221-225.
67. Friberg, Svedjeholm R, Soderquist B, Granfeldt H, Vikerfors T, Kallman J. Local gentamicin reduces sternal wound infections after cardiac surgery: A randomized controlled trial. Ann Thorac Surg 2005; 79: 153-161.
68. American Society of Health-System Pharmacists. ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. Am J Health Syst Pharm 1999; 56: 1839-1888.
69. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38: 1706-1715.
70. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20: 250-278.
71. Page CP, Bohnen JM, Fletcher JR, McManus AT, Solomkin JS, Wittmann DH. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 1993; 128: 79-88.
72. Lafreniere R, Berguer R, Seifert PC. Preparation of the operating room. In: Wilmore DW (ed.). ACSPSurgery: principles and practice 2004. WebMD, New York, NY, 2004: Pp12-13.
73. Society of Thoracic Surgeons Workforce on Evidence Based Surgery. Antibiotic Prophylaxis in Cardiac Surgery, Duration of Prophylaxis. 2005. Online. Ref Type: Report.
74. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334: 1209-1215.
75. Hauser GJ, Chan MM, Casey WF, Midgley FM, Holbrook PR. Immune dysfunction in children after corrective surgery for congenital heart disease. Crit Care Med 1991; 19: 874-881.
76. Ungerleider RM, Shen I, Yeh T, et al. Routine mechanical ventricular assist following the Norwood procedure - improved neurologic outcome and excellent hospital survival. Ann Thorac Surg 2004; 77: 18-22.
77. Maher KO, VanDerElzen K, Bove EL, Mosca RS, Chenoweth CE, Kulik TJ. A retrospective review of three antibiotic prophylaxis regimens for pediatric cardiac surgical patients. Ann Thorac Surg 2002; 74: 1195-1200.
78. Dagan O, Cox PN, Ford-Jones L, Ponsonby J, Bohn DJ. Nosocomial infection following cardiovascular surgery: Comparison of two periods, 1987 vs. 1992. Crit Care Med 1999; 27: 104-108.
79. Pollock EM, Ford-Jones EL, Rebeyka I, et al. Early nosocomial infections in pediatric cardiovascular surgery patients. Crit Care Med 1990; 18: 378-384.
80. Centers for Disease Control and Prevention. National nosocomial infection surveillance (NNIS) system report, data summary form January 1992-April 2000. Am J Infect. Control 2000; 28: 429-448.
81. Jonkers D, Swennen J, London N, Driessen C, Stobberingh E. Influence of cefazolin prophylaxis and hospitalization on the prevalence of antibiotic-resistant bacteria in the faecal flora. J Antimicrob Chemother 2002; 49: 567-571.
82. Kernodle DS, Barg NL, Kaiser AB. Low-level colonization of hospitalized patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrob Agents Chemother 1988; 32: 202-208.
83. Archer GL, Armstrong BC. Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. J Infect Dis 1983; 147: 642-649.
84. Archer GL. Alteration of cutaneous staphylococcal flora as a consequence of antimicrobial prophylaxis. Rev Infect Dis 1991; 13 Suppl 10: S805-809.
85. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001; 33: 1462-1468.
86. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Is prolonged antibiotic prophylaxis after major surgery associated with an increased risk of nosocomial bloodstream infection? J Am Coll Surg 2000; 190: 503-504.
87. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002; 46: 1619-1628.
88. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000; 101: 2916-2921.
89. Burke JP. Antibiotic resistance - squeezing the balloon? JAMA 1998; 280: 1270-1271.
90. Terpstra S, Noordhoek GT, Voesten HG, Hendriks B, Degener JE. Rapid emergence of resistant coagulase-negative staphylococci on the skin after antibiotic prophylaxis. J Hosp Infect 1999; 43: 195-202.
91. Kreisel D, Savel TG, Silver AL, Cunningham JD. Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity. Arch Surg 1995; 130: 989-993.
92. Saginur R, Croteau D, Bergeron MG. Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients. The ESPRIT Group. J Thorac Cardiovasc Surg 2000; 120: 1120-1130.
93. Sisto T, Laurikka J, Tarkka MR. Ceftriaxone vs cefuroxime for infection prophylaxis in coronary bypass surgery. Scand J Thorac Cardiovasc Surg 1994; 28: 143-148.
94. Hall JC, Christiansen K, Carter MJ, et al. Antibiotic prophylaxis in cardiac operations. Ann Thorac Surg 1993; 56: 916-922.
95. Beam T, Raab T, Spooner J, Balderman S, Aldridge J, Bhayana J. Single-dose antimicrobial prophylaxis in open heart surgery. Eur J Clin Microbiol 1984; 3: 598-604.
96. Nooyen SM, Overbeek BP, Brutel dIR, Storm AJ, Langemeyer JJ. Prospective randomized comparison of single-dose versus multiple-dose cefuroxime for prophylaxis in coronary artery bypass grafting. Eur J Clin Microbiol Infect Dis 1994; 13: 1033-1037.
97. Bucknell SJ, Mohajeri M, Low J, McDonald M, Hill DG. Single-versus multiple-dose antibiotics prophylaxis for cardiac surgery. Aust N Z J Surg 2000; 70: 409-411.
98. McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: A systematic review. Aust N Z J Surg 1998; 68: 388-396.
99. Hillis DJ, Rosenfeldt FL, Spicer WJ, Stirling GR. Antibiotic prophylaxis for coronary bypass grafting. Comparison of a five-day and a two-day course. J Thorac Cardiovasc Surg 1983; 86: 217-221.
100. Geroulanos S, Oxelbark S, Turina M. Perioperative antimicrobial prophylaxis in cardiovascular surgery. A prospective randomized trial comparing two day cefuroxime prophylaxis with four day cefazolin prophylaxis. J Cardiovasc Surg (Torino) 1986; 27: 300-306.
101. Jewell M, Davis Z, Fliegelman R, Guillory J, Sokalski S. Infection following coronary artery surgery. Comparison of two antibiotic prophylaxis regimens. Chest 1988; 93: 712-715.
102. Ariano RE, Zhanel GG. Antimicrobial prophylaxis in coronary bypass surgery: A critical appraisal. DICP 1991; 25: 478-484.
103. Kriaras I, Michalopoulos A, Turina M, Geroulanos S. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardiothorac Surg 2000; 18: 440-446.
104. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: Baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005; 140: 174-182.
105. Miller KW, McCoy HG, Chan KK, et al. Effect of cardiopulmonary bypass on cefazolin disposition. Clin Pharmacol Ther 1980; 27: 550-556.
106. Ortega GM, Marti-Bonmati E, Guevara SJ, Gomez IG. Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery. Am J Health Syst Pharm 2003; 60: 260-265.
107. Miglioli PA, Merlo F, Grabocka E, Padrini R. Effects of cardiopulmonary bypass on vancomycin plasma concentration decay. Pharmacol Res 1998; 38: 275-278.
108. Fellinger EK, Leavitt BJ, Hebert JC. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann Thorac Surg 2002; 74: 1187-1190.
109. Hatzopoulos FK, Stile-Calligaro IL, Rodvold KA, Sullivan-Bolyai J, Del Nido P, Levitsky S. Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. Pediatr Infect Dis J 1993; 12: 300-304.
110. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 2001; 7: 828-831.
111. Vuorisalo S, Pokela R, Syrjala H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998; 19: 234-239.